Scientists at the University of Münster report a major advance in light-powered chemistry for housane molecules on May 20, 2026. Using phot...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

Shares of Anthem BioSciences rose after Citi initiated coverage with a Buy rating and a target price of ₹870, implying over 20% upside. Ana...

Kailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....

Iambic and Takeda Pharmaceutical have formed a multi-year partnership valued at over $1.7 billion. This collaboration will leverage artific...

SandboxAQ, an AI startup originating from Alphabet's Google and backed by Nvidia, has released a substantial dataset to accelerate drug dis...

Glenmark Pharmaceuticals and Ichnos Sciences have formed an alliance called Ichnos Glenmark Innovation (IGI) to accelerate cancer drug disc...

A group of scientists led by Professor R. Sowdhamini at NCBS has identified the 33 small molecules from a database of over 3,30,000 small m...

A 2018 Lancet study says, India accounts for about a fifth of cardiovascular deaths globally.

The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children

The major hurdle has been that as these local cues are not consistent between cells; one needs systems that respond to multiple such cues.

A new test could revolutionise the discovery of new prescription drugs by determining which drugs are unlikely to work at an early stage.

For Connexios, this sale of its anti-diabetes molecules to Boehringer Ingelheim is the first out-licensing deal by an Indian life-sciences ...

The company has also entered into a discovery collaboration with biotechnology company Merck Serono International